Feb 18, 2021
Sobi publishes report for the fourth quarter and full-year 2020
Feb 16, 2021
Kineret® (anakinra) approved in Russia for the treatment of CAPS
Feb 03, 2021
Invitation - Presentation of Sobi's Q4 and FY 2020 results
Jan 20, 2021
Doptelet® (avatrombopag) approved in the EU for treatment of ITP
Dec 11, 2020
Doptelet® (avatrombopag) receives positive opinion from CHMP for treatment of ITP
Dec 10, 2020
Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNH
Dec 10, 2020
Emapalumab submission in China for primary HLH
Dec 07, 2020
Agenda: Sobi Capital Markets Day 2020
Nov 19, 2020
Sobi and Apellis announce first patient dosed in potentially registrational ALS study of pegcetacoplan
Nov 06, 2020
Strong Sobi presence at American Society of Hematology 2020 Annual Meeting
Oct 23, 2020
Invitation to the Sobi Capital Markets Day 2020
Oct 22, 2020
Sobi publishes report for the third quarter 2020
Oct 17, 2020
Emapalumab's efficacy confirmed by sensitivity analysis presented at ESID2020
Sep 30, 2020
Sobi and Selecta Biosciences announce topline data of SEL-212 from the phase 2 COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout
Sep 18, 2020
Orfadin® (nitisinone) receives positive opinion from CHMP for treatment of AKU
Sep 10, 2020
New England Journal of Medicine publishes positive final results from phase 1/2a study of BIVV001 in people with severe haemophilia A
Jul 13, 2020
Data Presented at ISTH2020 Strengthens Evidence for Both Elocta® and Alprolix® in Previously Untreated Patients With Haemophilia
Jul 06, 2020
Invitation - Presentation of Sobi's Q2 2020 Results
Jun 26, 2020
Successful Elocta Bid Means Increased Access for People With Haemophilia A in the UK
Jun 14, 2020
Sobi and Sanofi Donate up to 500 Million Additional IUs of Clotting Factor to WFH Humanitarian Aid Program